Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I lightened my PDEX. I like it long term, but agree this quarter could disappoint. Maybe they have massive interest in their new product with rapid reorders, but that seems unlikely. They have another smaller new product coming in 1q next year.
Wow, they're doing great. I had thought their recent success would be temporary, but these COVID names are sticking around longer than I expected.
APT to $16.30
OBCI +1.84 to $15.44
Looks like a stock market down, COVID stocks up day to me.
On APT, I don't see why margins would get eroded with COVID abating. I don't know, but I doubt that APT has raised the prices on their masks. If anyone has raised their prices it is more likely to be the distributors I would think. Also, although the ordinary masks market is getting saturated, I don't think the N95 mask market is getting saturated, I think there is still a shortage and will be for awhile.
GLGI made .03 number of pallets up but revenue down on "pricing structure"
Does that mean they had lower the pallet prices? Hopefully that is not a trend.
https://www.otcmarkets.com/filing/html?id=14438970&guid=UW-eUK1DvCKAv3h
SMDM Singing Machine is saying they will part of Amazon Prime day. They also have more to recoup from insurance and some Black Friday sales that slid into the coming quarter. On Amazon they have consistent recent reviews. Also, carpool karaoke microphone on Google trends is showing good traffic. Looks like it is shaping up to be a good quarter or two.
https://finance.yahoo.com/news/carpool-karaoke-microphone-featured-amazon-130000669.html
https://trends.google.com/trends/explore?q=Carpool%20karaoke%20microphone&geo=US
https://www.amazon.com/Singing-Machine-Bluetooth-Microphone-CPK545/product-reviews/B07SLFVGSC/ref=cm_cr_arp_mb_viewopt_srt?ie=UTF8&reviewerType=all_reviews&sortBy=recent&pageNumber=1
I own DTEA. I think they'll get a deal on exiting their leases and they have a lot of cash to cover most of the obligation.
APT sells N95 masks which is a much less competitive market.
APT another way to look at it is that news of the expansion could come out any day and drive the price of the stock up. There will definitely be continued high demand for the masks for awhile.
Revenue grew at 87% and will be between 80-120% and maybe more with all the new sales people and as COVID dissipates. With a p/e in the 50s seems like a good risk reward here.
Their quarters will be lumpy, but I would say this is just the beginning of huge quarters.
PDEX ($24.90) up 17% on 59% in revenue because of their new products. $0.64 for the quarter. They are rockin now. The new products are working and they will have a long pipeline with bigger and bigger TAM.
I'm glad to see GLGI margin improvements are "sticking" with no surprises.
Congrats on PGNT. I know you were talking about it when it was at a buck. I bought some around $2.57. Stock remains ridiculously cheap. But they have been able to execute.
The SMDM CC sounded very positive. They have been having trouble keeping the carpool karaoke mic in stock. They were selling 2000 a day at one point, now selling hundreds a day. I'm not sure how long this trend will last but I think now through the next year looks bright.
Thanks for the input Gilead23.
Here is some more GLGI analysis
GLGI - Any reason to think GLGI won't continue these .06 quarters?
CVLB - Sales and marketing expense came in way higher than I expected. They are spending alot of money to generate sales.
Some notes from the call:
Very upbeat on the call almost too much for me. Mentioned they think "The sky is the limit", "land grab" in the telehealth market.
There were many callers on the call. Maybe 7? - showing alot of interest in the company.
Talked about multiple new product possibilites.
When asked about uplisting they said it is a near term priority and they would do is as soon as possible and when pressed on a timeline said "I would hope within the year"
Said they spent about $100K cash and some more in stock to purchase the Veritas MD platform that probably $1-$5Million put into it.
Veritas MD platform is finished they are just adding a few final features and working on scalability of the platform.
They said pdf-simpli could get to $10M run rate.
About spending money they said they would accept new capital only in ways that is accretive and makes sense. "We care about the equity". There are "no big salaries" on our team. Not looking to make a decision to take on capital so that they'll get a paycheck. Concerned about cost of capital, what is the return for shareholders as they are one of the biggest.
Guidance for next year: no formal guidance. They said "Assuming current trends continue tough not to be 75 -100Million revenue range next year."
They said "We know we have great unit economics"
LEAT - Great quarter, and it is the next quarter that is the largest quarter. I don't think there has been any slowdown, and I think at first the distributors weren't taking as much new product, whereas that has now changed. They also talked about ecommerce being a large contributor. So the next quarter will probably be significant. In their press release from the previous quarter they had previously downplayed results not expecting much from this quarter. They were very upbeat on the conference call. They seemed almost disappointed that there was only one question.
SCIA 10Q from 8/7
Net Income down to zero.
"Thus, we expect revenue to be lower in the second half of 2020 compared to the first six months of this year."
https://www.otcmarkets.com/filing/html?id=14318113&guid=OOR6UH20MGpAhZh
Press Release is out, they do sound optimistic on next quarter, and that they will get new contract wins and orders that they can put into their backlog.
https://www.otcmarkets.com/stock/OPXS/news/Optex-Systems-Holdings-Inc-Announces-Third-Quarter-of-Fiscal-Year-2020-Financial-Highlights?id=270487
OPXS 10q out
Looks like the warrants obscured the numbers again and made it look like a loss. EBITDA doubled, but it seems like it was all due to higher gold prices for redemptions on gold they use on the lenses. So seems flat in actuality.
https://www.otcmarkets.com/filing/html?id=14325576&guid=K1R6UKC9-DOqE3h
LEAT 3.55 getting some love
ZYXI has been on a tear even despite that short attack article.
OPXS nice buys on OPXS. Announced they are now buying back shares.
I still use Yahoo even though they have pretty much destroyed all the usefulness of it. Recently I noticed that the earnings stopped showing up. I already have to go elsewhere to get the news since they cut the old stories off after the headline.
ZYXI is doing great. And now is being awarded a PE of 63 for their great performance. Meanwhile they are growing revenues at 66% and still accelerating. Very interesting setup.
SMSI results out, look pretty good. 57% rev growth. .10 nongaap .03 gaap versus .00 last year. "Immense opportunities everywhere we look" - from conference call. Rev guidance in Q2 down 4-9% due to COVID
https://www.otcmarkets.com/stock/SMSI/news/story?e&id=1595104
SCIA seemed to have nothing special in their report.
ZYXI ($16.40 AH) another great quarter
Revenues up 66%
Orders up 126%
Guidance for 70% to 75% rev growth.
Hiring pace now at 48 reps a month
Halfway done with a new model of bood volume monitor
https://www.otcmarkets.com/stock/ZYXI/news/story?e&id=1587006
He said something to suggest that the new wins will be potentially larger than anything they have done in 2019. Not sure if the 4 that got pushed are of the larger variety or not. He also said the larger deals will take a longer engagement. So that might suggest that these 4 are bigger deals since they are taking longer.
11 customer wins this quarter versus 8 wins last quarter
ZYXI is recovering nicely
SMSI - I thought it was against your rules to hold stocks through earnings. I mean I bought some at $5.60 today also because I thought the results would be good, and I thought the call was great, but I thought you always traded the expectations. Anyway, I hope it goes to the moon tomorrow, but I'm not sure because this stock sells off fairly easily.
ZYXI (13.30 +11% in after hours) had another great quarter. 52% revenue growth yoy, 30% increase in EBITDA yoy. Full year revenue estimate is approximately 65% to 76% above 2019 revenue. The blood volume monitor was FDA approved last year. Hired 40 reps since the beginning of the year.
http://zynexmed.investorroom.com/2020-02-27-Zynex-Announces-2019-Fourth-Quarter-and-Full-Year-Earnings
OBCI is this getting roped into the Corona virus story?
Zynex Announces 2019 Fourth Quarter and Full Year Earnings
ENGLEWOOD, Colo., Feb. 27, 2020 /PRNewswire/ --
2019 Full Year
Revenue increased 42% year over year to $45.5 million
Net income $9.5 million; Diluted EPS $0.28
2019 Revenue, net income and Adjusted EBITDA are the highest in Company history
Adjusted EBITDA increased 11% to $12.1M
2019 Fourth Quarter
Revenue increased 52% year over year to $14.2 million
Orders increased 129%
Net income of $2.9 million; Diluted EPS $0.09
Adjusted EBITDA increased 30% to $4.1 million
Fourteenth consecutive quarter of positive net income
Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today reported financial results for its fourth quarter and full year ended December 31, 2019.
Zynex
Fourth Quarter Financial Results Summary:
For the fourth quarter, the Company reported net revenue of $14.2 million, a 52% increase over the fourth quarter of 2018. Gross margins were 80% in the fourth quarter of 2019 and net income was $2.9 million.
Adjusted EBITDA was $4.1 million in the fourth quarter of 2019.
The Company generated $2.1 million of cash from operations during the fourth quarter of 2019. As of December 31, 2019, the Company had working capital of $17.4 million a 137% increase compared to $7.3 million at December 31, 2018. Cash on hand was $14.0 million at the end of the fourth quarter.
President and CEO Commentary:
Thomas Sandgaard, CEO said: "In the fourth quarter, we posted revenue of $14.2 million, which is the highest quarterly revenue in the history of the Company and net income of $2.9 million. Orders grew 129% compared to the fourth quarter of 2018 up from 95% year-over-year growth in the third quarter.
"In the fourth quarter, we continued to focus on the execution of our growth strategy and the related growth of our sales force. We expect the addition of new sales reps to have an impact on order and revenue growth this year and going forward. In addition, we continue to invest in our infrastructure to support the increase in order volume.
"We continue to advocate for pain patients, and for physicians to prescribe our NexWave technology as the first line of defense in treating chronic and acute pain without side effects. We are dedicated to promoting our technology in an effort to remove patient addiction and other side effects from prescription opioids."
First Quarter and Full Year 2020 Guidance:
The estimate range for the first quarter revenue is between $14.0 and $14.5 million with Adjusted EBITDA between $2.3 and $2.8 million as we continue to invest in growing our sales force. The revenue estimate is approximately 52% to 58% above 2019 first quarter revenue of $9.2 million. First quarter revenue is historically affected by health insurance deductibles not being met in the beginning of the year.
Full year 2020 revenue is estimated between $75.0 and $80.0 million with Adjusted EBITDA between $15.0 and $18.0 million. The full year revenue estimate is approximately 65% to 76% above 2019 revenue of $45.5 million.
Conference Call and Webcast Details:
Thursday, February 27, 2020 at 2:15 p.m. MT – 4:15 p.m. ET
To register and participate in the webcast, interested parties should click on the following link or dial in approximately 10-15 minutes prior to the webcast:
https://www.webcaster4.com/Webcast/Page/1487/33247
US PARTICIPANT DIAL IN (TOLL FREE):
1-844-825-9790
INTERNATIONAL DIAL IN:
1-412-317-5170
Canada Toll Free:
1-855-669-9657
I also thought the FDA approval would drive the stock much higher on the news, but the market seems to be shrugging it off. I'm looking forward to tomorrow's earnings and guidance for next quarter.